Neurent Medical Expands Access Through Cigna's Policy Change
In a groundbreaking development for patients managing chronic rhinitis, Neurent Medical is thrilled to share that Cigna Healthcare has made a significant policy update affecting the coverage for NEUROMARK treatment. Effective September 15, Cigna has removed CPT 31242, the code for posterior nasal nerve ablation using radiofrequency, from its Experimental & Investigational (E&I) list. This important change is set to remove a crucial barrier for ENT physicians, enabling broader access to this innovative treatment for their patients.
Improved Patient Access to Treatments
This policy revision is a major advancement for patients who have been seeking effective solutions for chronic rhinitis. Cigna's acknowledgment of the therapeutic value of the posterior nasal nerve ablation procedure is expected to enhance the treatment landscape significantly. With this change, ENT physicians will now have increased flexibility and an opportunity to offer cutting-edge care to Cigna patients who suffer from the burdensome symptoms of chronic rhinitis, including persistent nasal congestion and rhinorrhea.
Comments from Neurent Medical's Leadership
Brian Shields, CEO of Neurent Medical, emphasized the importance of this moment, stating, "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continuing to build on our extensive evidence base and collaborating with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to facilitate widespread adoption across the U.S. healthcare system." This commitment demonstrates Neurent's dedication to improving patient outcomes through innovative technology.
Understanding NEUROMARK Technology
The NEUROMARK System utilizes advanced technology to deliver impedance-controlled, low-power radiofrequency (RF) energy. This method disrupts the parasympathetic nerve signals that contribute to the key symptoms of chronic rhinitis. Dr. Peter Manes, an Associate Professor at Yale School of Medicine, added, "Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions. This policy update is significant and facilitates the work of otolaryngologists to offer a modern treatment supported by evidence with fewer administrative challenges. The expanding evidence base increases the likelihood that patients will access such technologies."
Key Updates to Note for Providers
Providers should be aware of a few key points following this policy change:
- CPT 31242 is no longer classified as investigational by Cigna.
- Precertification is not required under the updated policy; however, it is essential to confirm benefits according to individual plans.
- This policy change supports more streamlined access to NEUROMARK for eligible patients, making the treatment more readily available.
About Neurent Medical
Neurent Medical is a pioneering organization in the field of non-surgical treatments for chronic inflammatory sinonasal diseases. Their focus on targeting and disrupting hyperactive autonomic nerves has proven effective in alleviating the symptoms associated with these conditions. The innovative NEUROMARK technology features a distinct design and advanced algorithmic control that enables healthcare providers to safely and accurately disrupt multiple nerve branches in a single session. This advancement aims to enhance the quality of life for patients suffering from chronic rhinitis.
Neurent operates with a vision of transforming chronic rhinitis management. With headquarters in Galway, Ireland, and a U.S. presence in Braintree, MA, Neurent Medical is positioned to make a significant impact on this crucial area of health care. For further information on their offerings and progress, visit their website.
Frequently Asked Questions
What is NEUROMARK?
NEUROMARK is a non-surgical treatment for chronic rhinitis that targets hyperactive autonomic nerves to alleviate symptoms such as nasal congestion and runny nose.
How has Cigna's policy change affected NEUROMARK treatment?
Cigna's removal of CPT 31242 from its E&I list allows for broader accessibility of NEUROMARK treatments for patients without requiring precertification.
What are the symptoms of chronic rhinitis?
Individuals suffering from chronic rhinitis often experience persistent nasal congestion, rhinorrhea (runny nose), sneezing, and post-nasal drip.
Who can benefit from NEUROMARK?
Patients struggling with chronic rhinitis who are seeking effective treatment options can benefit from the NEUROMARK procedure.
What does the NEUROMARK procedure entail?
The NEUROMARK procedure utilizes low-power radiofrequency energy to disrupt nerve signals responsible for chronic rhinitis symptoms, providing symptom relief.
